The critical anabolic and trophic role of signaling by insulin-like growth factors (IGF) I and II via the type-I IGF receptor (IGF-IR) is reviewed throughout the life of skeletal myocytes. The proliferative effects of IGF-IR stimulation, both during embryogenesis and during satellite cell proliferation following denervation or muscle injury, are mediated primarily through activation of mitogen-activated protein kinases. Signaling through phosphatidylinositol 3-kinase is essential to muscle protein synthesis and glucose uptake and may contribute to the observed resilience of mature muscle to programmed cell death. Degeneration or inhibition of the GH-IGF-I axis by aging, cachexia, sepsis, diabetes, drugs, and disuse all enhance muscle catabolism, and opposition of these effects by IGF-I may form the basis of effective myotherapy.
Insulin-like growth factor I (IGF-I) is a widely distributed trophic hormone expressed primarily by liver and skeletal muscle, capable of mediating autocrine, paracrine, or endocrine effects. IGF-I was originally referred to as "somatomedin" to reflect its expression in response to growth hormone (GH) stimulation and its ability to mediate some of the growth-promoting effects of GH. Early studies compared the metabolic effect of IGF-I and insulin on muscle, including stimulation of protein metabolism, glucose transport, and glycogen and triglyceride synthesis. More recently, research has shifted to the role of IGFs in myogenesis and differentiation and in response to senescence, physical injury, and disease states. This review focuses on the two principal intracellular signaling pathways activated by IGF-I within skeletal muscle, phosphatidylinositol 3-kinase and the mitogen-activated protein kinase cascade. Alterations in these pathways are considered in the pathogenesis of the trophic and anabolic roles of IGF-I in muscle development, aging, metabolic deficiency states, and myopathic disease.
THE IGF-I RECEPTOR MEDIATES THE CELLULAR EFFECTS OF IGF-I
Both IGF-I and IGF-II are highly structurally related to insulin (49 and 47% peptide identity, respectively) but, unlike insulin, are not cleaved during processing to produce a heterodimer (Van den Brande, 1994) . IGFs are synthesized primarily in the liver, but are also produced locally in tissues, including skeletal muscle, where they can exert autocrine or paracrine effects. IGFs bind to six known IGF binding proteins (IGFBPs), which stabilize IGFs in serum and regulate their access to target tissues. IGFBP-3 binds nearly 95% of IGF-I in serum (Jones et al., 1995) , and its expression is regulated by GH (Beauloye et al., 1999) , making it arguably the most important binding protein for control of the GH-IGF-I axis. A full discussion of IGFBPs, their regulation, and their implications in disease states can be found in several recent and au-
